MA40623A - Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie - Google Patents

Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie

Info

Publication number
MA40623A
MA40623A MA040623A MA40623A MA40623A MA 40623 A MA40623 A MA 40623A MA 040623 A MA040623 A MA 040623A MA 40623 A MA40623 A MA 40623A MA 40623 A MA40623 A MA 40623A
Authority
MA
Morocco
Prior art keywords
elsiglutide
induced diarrhea
gastrointestinal mucositis
including chemotherapy
treat gastrointestinal
Prior art date
Application number
MA040623A
Other languages
English (en)
French (fr)
Inventor
Selma Calcagnile
Ruben Giorgino
Carsten Boye Knudsen
Cecilia Moresino
Simona Roncoroni
Riccardo Spezia
Fabio Trento
Original Assignee
Helsinn Healthcare Sa
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helsinn Healthcare Sa, Zealand Pharma As filed Critical Helsinn Healthcare Sa
Publication of MA40623A publication Critical patent/MA40623A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/26Glucagons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA040623A 2014-09-10 2015-09-02 Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie MA40623A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462048520P 2014-09-10 2014-09-10

Publications (1)

Publication Number Publication Date
MA40623A true MA40623A (fr) 2016-03-17

Family

ID=54548212

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040623A MA40623A (fr) 2014-09-10 2015-09-02 Utilisation d'elsiglutide pour traiter la mucosité gastro-intestinale, y compris la diarrhée induite par la chimiothérapie

Country Status (18)

Country Link
US (1) US20160067311A1 (https=)
EP (1) EP3191115A1 (https=)
JP (1) JP2017532308A (https=)
KR (1) KR20170052661A (https=)
CN (1) CN107073081A (https=)
AR (1) AR103119A1 (https=)
AU (1) AU2015313919A1 (https=)
BR (1) BR112017004577A2 (https=)
CA (1) CA2959110A1 (https=)
CL (1) CL2017000563A1 (https=)
EA (1) EA201790552A1 (https=)
IL (1) IL250928A0 (https=)
MA (1) MA40623A (https=)
MX (1) MX2017003166A (https=)
PH (1) PH12017500426A1 (https=)
SG (1) SG11201701690WA (https=)
TW (1) TW201613634A (https=)
WO (1) WO2016038455A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170087216A1 (en) * 2015-09-17 2017-03-30 Helsinn Healthcare Sa Therapeutic Uses of Elsiglutide
US11389424B2 (en) 2017-03-09 2022-07-19 Napo Pharmaceuticals, Inc. Methods and compositions for treating chemotherapy-induced diarrhea
BR112019026711A2 (pt) * 2017-06-16 2020-06-30 Zealand Pharma A/S regimes de dosagem para a administração de análogos de peptídeo semelhante a glucagon- 2 (glp-2)
MX2022016367A (es) * 2020-06-19 2023-01-30 Napo Pharmaceuticals Inc Metodos y composiciones para el tratamiento de la diarrea inducida por quimioterapia.
CN115054683B (zh) * 2022-05-19 2023-06-09 唐颢 胰高血糖素样肽-2在制备缓解阿霉素心脏毒性药物中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101163483A (zh) * 2005-04-22 2008-04-16 诺瓦西股份有限公司 使用活性维生素d化合物或其模拟物治疗、预防和缓解与化疗和放疗有关的肺部疾患
DE602006020123D1 (de) * 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
EP2314616A1 (en) * 2009-10-23 2011-04-27 Ferring B.V. Peptidic GLP-2 agonists

Also Published As

Publication number Publication date
JP2017532308A (ja) 2017-11-02
IL250928A0 (en) 2017-04-30
KR20170052661A (ko) 2017-05-12
TW201613634A (en) 2016-04-16
CL2017000563A1 (es) 2017-09-29
US20160067311A1 (en) 2016-03-10
WO2016038455A1 (en) 2016-03-17
MX2017003166A (es) 2017-06-19
CA2959110A1 (en) 2016-03-17
BR112017004577A2 (pt) 2018-01-23
AR103119A1 (es) 2017-04-19
PH12017500426A1 (en) 2017-07-31
AU2015313919A1 (en) 2017-03-16
EP3191115A1 (en) 2017-07-19
EA201790552A1 (ru) 2017-08-31
SG11201701690WA (en) 2017-04-27
CN107073081A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
MX2021000077A (es) Composiciones que comprenden cepas bacterianas.
MX2019003623A (es) Composiciones y metodos para el tratamiento de afecciones oftalmicas.
MX2018006239A (es) Composiciones que comprenden cepas bacterianas.
MX2018006398A (es) Composiciones que comprenden cepas bacterianas.
MX2018006399A (es) Composiciones que comprenden cepas bacterianas.
MX2017016529A (es) Composiciones que comprenden cepas bacterianas.
MX2017016564A (es) Composiciones que comprenden cepas bacterianas.
MX2017016525A (es) Composiciones que comprenden cepas bacterianas.
MX2017016560A (es) Composiciones que comprenden cepas bacterianas.
MX2020005213A (es) Inhibidores de proteina cinasa 2 activada por proteina cinasa activada por mitogeno (mk2) y sus usos.
PH12016501763B1 (en) Multispecific antibodies
MX2017000363A (es) Inhibicion de la via de notch.
SG10201808940WA (en) Nox inhibitor and nfкb inhibitor containing methoxyflavone
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
PH12017500426A1 (en) Use of elsiglutide to treat gastrointestinal mucositis including chemotherapy-induced diarrhea
PH12017501864A1 (en) Compositions and methods for treating autism
MX2021005080A (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos para tratar o prevenir la fibrosis usando las mismas.
MX379126B (es) Formulación de factor viii.
PH12018500339A1 (en) Lysobactin for use in the treatment of bovine mastitis
TR201620309A2 (tr) Metformi̇n hi̇droklori̇t ve pi̇ogli̇tazon hi̇droklori̇ti̇n farmasöti̇k bi̇leşi̇mleri̇
UA114708U (uk) Тяговий привід електробуса
AU364097S (en) Transportable accommodation pod called Gunya Pod
IN2014CH00035A (https=)
UA99992U (ru) 2-оксо-4-фенил-5-циано-1,2,3,4-тетрагидропиридин-6-тиолат n-метилморфолиния
AU365961S (en) Clasp